Mainz Biomed (NASDAQ:MYNZ) Trading Up 7% – Here’s Why

Mainz Biomed NV (NASDAQ:MYNZ) shares were up 7% during mid-day trading on Tuesday . The company traded as high as $2.12 and last traded at $1.98. Approximately 1,164,831 shares changed hands during mid-day trading, an increase of 697% from the average daily volume of 146,151 shares. The stock had previously closed at $1.85.

Mainz Biomed Price Performance

The firm has a market capitalization of $6.81 million, a PE ratio of -0.03 and a beta of 0.21. The business has a 50-day moving average of $1.90 and a 200 day moving average of $3.65. The company has a current ratio of 1.32, a quick ratio of 1.26 and a debt-to-equity ratio of 0.14.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mainz Biomed stock. Virtu Financial LLC purchased a new stake in shares of Mainz Biomed NV (NASDAQ:MYNZ) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned about 0.92% of Mainz Biomed at the end of the most recent reporting period.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.